The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii | Zendy

Shawn R. Lockhart | Zendy; Annette W. Fothergill | Zendy; Naureen Iqbal | Zendy; Carol B. Bolden | Zendy; Nina T. Grossman | Zendy; Edward P. Garvey | Zendy; Stephen Brand | Zendy; William J. Hoekstra | Zendy; Robert J. Schotzinger | Zendy; Elizabeth A. Ottinger | Zendy; Thomas F. Patterson | Zendy; Nathan P. Wiederhold | Zendy

Open Access

The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii

Author(s) -

Shawn R. Lockhart,

Annette W. Fothergill,

Naureen Iqbal,

Carol B. Bolden,

Nina T. Grossman,

Edward P. Garvey,

Stephen Brand,

William J. Hoekstra,

Robert J. Schotzinger,

Elizabeth A. Ottinger,

Thomas F. Patterson,

Nathan P. Wiederhold

Publication year - 2016

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02770-15

Subject(s) - cryptococcus neoformans , cryptococcus gattii , cryptococcus , fluconazole , microbiology and biotechnology , cryptococcosis , potency , biology , in vitro , antifungal , biochemistry

Thein vitro activities of the novel fungal Cyp51 inhibitor VT-1129 were evaluated against a large panel ofCryptococcus neoformans andCryptococcus gattii isolates. VT-1129 demonstrated potent activities against bothCryptococcus species as demonstrated by low MIC50 and MIC90 values. ForC. gattii , thein vitro potency was maintained against all genotypes. In addition, significantly lower geometric mean MICs were observed for VT-1129 than for fluconazole againstC. neoformans , including isolates with reduced fluconazole susceptibility.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research